<DOC>
	<DOCNO>NCT01121354</DOCNO>
	<brief_summary>The purpose study demonstrate safety pharmacokinetics Cefazolin 2g Injection USP Dextrose Injection USP DUPLEXÂ® Drug Delivery System Cefazolin 1.5g Injection USP Dextrose Injection USP daily dose 6g healthy adult subject 11 day administration .</brief_summary>
	<brief_title>Pharmacokinetics Safety Cefazolin 2g DUPLEX</brief_title>
	<detailed_description>B. Braun Medical Inc. intend conduct human PK study obtain marketing approval Cefazolin 2g United States identical indication already approve 1g strength . A pharmacokinetic study conduct Cefazolin 2g product manufacture B. Braun Medical Inc. Cefazolin 1.5g dose prepare use 10g Cefazolin pharmacy bulk 5 % Dextrose . The clinical study propose protocol design evaluate pharmacokinetic characteristic 2g 1.5g Cefazolin Dextrose healthy subject maximum recommended infusion dose 6g per day per FDA 's recommendation . The study design simulate clinical practice overall experience cephalosporin administration . Cefazolin may reconstitute dextrose ( number diluent recommend innovator 's package insert ) order achieve osmolality appropriate intravenous infusion . According B. Braun 's approved package insert Cefazolin 1g , maximum dose 1.5g Cefazolin Injection USP Dextrose Injection USP 1.5 gram every 6 hour severe , life-threatening infection . In rare instance , dose 12 gram Cefazolin per day use . Lower dos state B. Braun package insert .</detailed_description>
	<mesh_term>Cefazolin</mesh_term>
	<criteria>Healthy subject , male female Age : 18 70 year ( inclusive ) time screen . Females nonchild bear potential ( surgically sterile [ hysterectomy bilateral tubal ligation ] postmenopausal &gt; = 1 year follicle stimulate hormone [ FSH ] &gt; 40 U/L ) . Healthy , determine prestudy medical evaluation ( medical history , physical examination , vital sign , electrocardiogram , clinical laboratory evaluation ) . Subject voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent Health Insurance Portability Accountability Act ( HIPAA ) Authorization prior perform screen procedure . Known allergy hypersensitivity betalactam/cephalosporin antibiotic , corn product ingredients Investigational Products Subjects impaired renal function base CockcroftGault formula use actual body weight , i.e . estimate creatinine clearance &lt; = 80 mL/min ( perform Screening ) Body Mass Index ( BMI ) &lt; 20.0 &gt; 30.0 kg/m^2 Body Weight &lt; 50.0 kg White Blood Count ( WBC ) &lt; 3.5 x10^3/uL &gt; ULN absolute neutrophil count ( ANC ) &lt; 1.5 x10^3/uL &gt; ULN Alarine aminotransferase aspartate aminotransferase &gt; upper limit normal Other laboratory test outside normal limit , consider investigator , clinically significant . Use medication chronic basis . Takes medication interferes study drug study procedure include aminoglycosides , anticoagulant , probenecid . Use counter ( OTC ) medication ( include vitamin ) , prescription medication , herbal remedy 14 day prior Day 1 end study . By exception , acetaminophen &lt; = 1 gram per day permit . Tobacco use last 2 month prior enrollment . Positive screen test Hepatitis B surface antigen , Hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody . Positive urine drug test ( cocaine , amphetamine , barbiturate , opiate , benzodiazepine , cannabinoids , etc . ) Screening Day 1 Positive blood test ethanol screen Day 1 . At screening , subject clinically relevant ECG change , assess PI designee . Concurrent acute chronic infection ( e.g . viral infection , except chronic recurrent herpes infection ) History ongoing alcohol abuse drug abuse ( within last 2 year ) . Received Investigational drug device within 30 day first dose study drug Clinically relevant medical condition likely interfere evaluation trial drug , e.g . COPD , metabolic disorder ( clinical subclinical diabetes mellitus ) , history malignant disease ( within last 5 year ) , autoimmune disease , cardiovascular disease Any plan medical intervention personal event might interfere ability comply study requirement Any condition , opinion principal investigator , would compromise safety patient quality data Unable unwilling adhere studyspecified procedure restriction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Cefazolin</keyword>
	<keyword>Caphalosporin</keyword>
	<keyword>antibiotic</keyword>
	<keyword>gram positive</keyword>
	<keyword>Infection control</keyword>
</DOC>